Although it is well known that myeloproliferative neoplasms occur in younger patients, few large cohorts of such patients have been reported. Thus, our knowledge about circumstances of diagnosis, outcome and treatment is limited, especially for children and young adults. We therefore performed a systematic review of cases, published since 2005, concerning patients aged below 20 years at the time of diagnosis of essential thrombocythemia or polycythemia vera. We identified 396 cases of essential thrombocythemia and 75 of polycythemia vera. The median age at diagnosis was 9.3 and 12 years, respectively, and females constituted 57.6% and 45% of the groups, respectively. Half of the patients were asymptomatic at diagnosis. The proportion of so-called triple negativity was high: 57% in essential thrombocythemia and 73% in polycythemia vera. The incidence of thrombosis during the follow-up was 9.3% in patients with polycythemia vera and less, 3.8%, in those with essential thrombocythemia. Venous events were predominant (84.2%), with hemorrhagic episodes being rarer (<5%). The risk of evolution also seemed low (2% to myelofibrosis and no reports of acute leukemia), but the median follow-up was only 50 months. Survival curves were not available. Half of the patients received an antithrombotic drug and 40.5% received a cytoreductive drug. All data should be analyzed with care because of the proportion of missing data (10.7% to 74.7%). This review highlights interesting points concerning this population of young patients with myeloproliferative neoplasms, including that such patients were identified as negative for all common driver mutations, but also shows the need for larger contemporary cohorts with longer follow-up to assess the true prognosis of these patients.

Centre d'Investigation Clinique Hôpital St Louis Paris France

Department of Haematology Guy's and St Thomas' NHS Trust London UK

Institute of Hematology and Blood Transfusion Prague Czech Republic

Service d'Hématologie Clinique Institut de Cancéro Hématologie Centre Hospitalier Régional et Universitaire de Brest Brest France

Zobrazit více v PubMed

Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017;92(1): 94–108. PubMed

Barbui T, Barosi G, Birgegard G, et al. European LeukemiaNet Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–770. PubMed PMC

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. PubMed

Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–2513. PubMed PMC

Boddu P, Masarova L, Verstovsek S, et al. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol. 2018;97(1):109–121. PubMed

Palandri F, Latagliata R, Polverelli N, et al. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. Leukemia. 2015;29(6):1344–1349. PubMed

Barbui T, Thiele J, Carobbio A, et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood. 2012;120(3):569–571. PubMed

Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica. 2003;88(1):13–18. PubMed

Cario H, McMullin MF, Pahl HL. Clinical and hematological presentation of children and adolescents with polycythemia vera. Ann Hematol. 2009;88(8):713–719. PubMed PMC

Costa G, Petit A, Ianotto JC, et al. Thrombocytémie essentielle (TE) chez l’enfant et le jeune adulte. Rev Oncol Hematol Ped. 2016;4(4):253–254.

El-Moneim AA, Kratz CP, Böll S, Rister M, Pahl HL, Niemeyer CM. Essential versus reactive thrombocythemia in children: retrospective analyses of 12 cases. Pediatr Blood Cancer. 2007;49(1):52–55. PubMed

Fu R, Liu D, Cao Z, et al. Distinct molecular abnormalities underlie unique clinical features of essential thrombocythemia in children. Leukemia. 2016;30(3):746–749. PubMed PMC

Giona F, Teofili L, Moleti ML, et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood. 2012;119(10): 2219–2227. PubMed

Giona F, Teofili L, Capodimonti S, et al. CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. Blood. 2014;123(23):3677–3679. PubMed

Ismael O, Shimada A, Hama A, et al. Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children. Pediatr Blood Cancer. 2012;59(3): 530–535. PubMed

Karow A, Nienhold R, Lundberg P, et al. Mutational profile of childhood myeloproliferative neoplasms. Leukemia. 2015;29(12): 2407–2409. PubMed

Langabeer SE, Haslam K, McMahon C. CALR mutations are rare in childhood essential thrombocythemia. Pediatr Blood Cancer. 2014;61(8):1523. PubMed

Nakatani T, Imamura T, Ishida H, et al. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia. Pediatr Blood Cancer. 2008;51(6):802–805. PubMed

Putti MC, Pizzi M, Bertozzi I, et al. Bone marrow histology for the diagnosis of essential thrombocythemia in children: a multi-center Italian study. Blood. 2017;129(22): 3040–3042. PubMed

Randi ML, Geranio G, Bertozzi I, et al. Are all cases of paediatric essential thrombocythemia really myeloproliferative neoplasms? Analysis of a large cohort. Br J Haematol. 2015;169(4):584–589. PubMed

Randi ML, Putti MC, Scapin M, et al. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood. 2006;108(10): 3600–3602. PubMed

Sekiya Y, Okuno Y, Muramatsu H, et al. JAK2, MPL, and CALR mutations in children with essential thrombocythemia. Int J Hematol. 2016;104(2):266–267. PubMed

Teofili L, Cenci T, Martini M, et al. The mutant JAK2 allele burden in children with essential thrombocythemia. Br J Haematol. 2009;145(3):430–432. PubMed

Teofili L, Giona F, Martini M, et al. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood. 2007;110(9):3384–3386. PubMed

Veselovska J, Pospisilova D, Pekova S, et al. Most pediatric patients with essential thrombocythemia show hypersensitivity to erythropoietin in vitro, with rare JAK2 V617F-positive erythroid colonies. Leuk Res. 2008;32(3):369–377. PubMed

Aladily TN, Mohammad RS, Al-Khader A, Awidi AS. Essential thrombocythemia in a two-year-old child, responsive to hydroxyurea but not aspirin. Oman Med J. 2017;32(3):243–246. PubMed PMC

Beatrice JM, Garanito MP. Essential thrombocythemia: a rare disease in childhood. Rev Bras Hematol Hemoter. 2013;35(4):287–289. PubMed PMC

Dua V, Yadav SP, Kumar V, Saxena R, Sachdeva A. Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea. Int J Hematol. 2012;96(6):810–813. PubMed

Hermeziu B, Franchi-Abella S, Plessier A, et al. Budd-Chiari syndrome and essential thrombocythemia in a child: favorable outcome after transjugular intrahepatic portosystemic shunt. J Pediatr Gastroenterol Nutr. 2008;46(3):334–337. PubMed

Hwang J, Lee W. A case of essential thrombocythemia in an 8-year-old boy. Pediatr Hematol Oncol. 2008;25(4):325–330. PubMed

Jaime-Perez JC, Gomez-Almaguer D. Platelet refractoriness to classical agonists in a child with essential thrombocythemia. Platelets. 2005;16(1):61–62. PubMed

Jensen AW, Tefferi A, Arndt CA. Cerebral venous sinus thrombosis associated with essential thrombocytosis in a pediatric patient. J Pediatr Hematol Oncol. 2007;29(3):156–159. PubMed

Kanai A, Morokawa H, Matsuda K, Shimazaki E, Nakazawa Y. Efficacy and safety of anagrelide in childhood essential thrombocythemia. Pediatr Int. 2017;59(9): 1017–1018. PubMed

Khan AA, Kumar V, Anand I, Kumar M, Sharma P, Bhargava M. JAK2 mutation-negative essential thrombocythemia in a child presenting with cerebral venous thrombosis. Hematol Oncol Stem Cell Ther. 2012;5(1): 66–68. PubMed

Kurosawa H, Okuya M, Matsushita T, et al. JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis. J Pediatr Hematol Oncol. 2009;31(9):678–680. PubMed

Lackner H, Urban C, Benesch M, et al. Long-term use of anagrelide in the treatment of children with essential thrombocythemia. Eur J Haematol. 2006;77(4):358–359. PubMed

Langabeer SE, Haslam K, McMahon C. A prenatal origin of childhood essential thrombocythemia. Br J Haematol. 2013;163(5): 676–678. PubMed

Bertrand A, Heissat S, Caron N, et al. Deep vein thrombosis revealing myeloproliferative neoplasm in two adolescents. Arch Ped. 2014;21(5):497–500. PubMed

Pulini S, D’Amico E, Basilico R, et al. Portal venous thrombosis in a young patient with idiopathic myelofibrosis and intrahepatic extramedullary hematopoiesis: a difficult diagnosis, prognosis and management. Leukemia. 2007;21(11):2373–2375. PubMed

Robins EB, Niazi M. Essential thrombocythemia in a child with elevated thrombopoietin concentrations and skeletal anomalies. Pediatr Blood Cancer. 2008;50(4):859–861. PubMed

Roy NB, Treacy M, Kench P. Childhood essential thrombocythemia. Br J Haematol. 2005;129(5):567. PubMed

Scherer S, Ferrari R, Rister M. Treatment of essential thrombocythemia in childhood. Pediatr Hematol Oncol. 2003;20(5):361–365. PubMed

Singh A, Nityanand S, Sonker A, Kumar S. Successful use of the cell separator Hemonetics multicomponent collection system+ for therapeutic thrombocytapheresis in a low body weight child of essential thrombocythemia. Asian J Transfus Sci. 2015;9(2):207–209. PubMed PMC

Slone JS, Smith MC, Seegmiller AC, Sidonio RF, Yang E. Idiopathic myelofibrosis in children: primary myelofibrosis, essential thrombocythemia, or transient process? J Pediatr Hematol Oncol. 2013;35(7):559–565. PubMed

Szegedi I, Benko I, Mero G, Prinzinger A, Kappelmayer J, Kiss C. Long-lasting partial remission by interferon-alpha treatment in a child with essential thrombocythemia. Pediatr Blood Cancer. 2007;49(5):744–747. PubMed

Tokgoz H, Caliskan U, Yüksekkaya HA, Kucukkaya R. Essential thrombocythemia with Mpl W515K mutation in a child presenting with Budd-Chiari syndrome. Platelets. 2015;26(8):805–808. PubMed

Vafaie M, Jaseb K, Ghanavat M, Pedram M, Rahiminia T. Asymtomatic [sic] essential thrombocythemia in a child: a rare case report. Int J Hematol Oncol Stem Cell Res. 2013;7(2):35–37. PubMed PMC

Wigton JC, Tersak JM. JAK2+ Essential Thrombocythemia in a young girl with Budd-Chiari syndrome: diagnostic and therapeutic considerations when adult disease strikes the young. J Pediatr Hematol Oncol. 2016;38(1):70–73. PubMed

Benedik-Dolni ar M, Homan M, Brecelj J. JAK2V617F mutation in a 9-year-old girl with polycythemia vera and Budd-Chiari syndrome: a case report. J Pediatr Hematol Oncol. 2012;34(3):243–244. PubMed

Berman JN, Greer WL, Archambeault S, et al. JAK2 V617F positive polycythemia vera in a child with neurofibromatosis type I. Pediatr Blood Cancer. 2008;51(5):689–691. PubMed

Braconnier O, Monpoux F, Affanetti M, Bérard E, Sirvent N. [Polycythemia vera and JAK-2 mutation in childhood: a case report]. Arch Pediatr. 2007;14(10):1202–1205. PubMed

Coskun ME, Height S, Dhawan A, Hadzic N. Ruxolitinib treatment in an infant with JAK2+ polycythemia vera-associated Budd-Chiari syndrome. BMJ Case Rep. 2017;2017. PubMed PMC

Goldstein G, Maor J, Kleinbaum Y, Palumbo M, Sidi Y, Salomon O. Budd-Chiari syndrome in very young adult patients with polycythemia vera: report of case series with good outcome with direct thrombin inhibitor treatment. Blood Coagul Fibrinolysis. 2013;24(8):848–853. PubMed

Guo HX, Chan GC, Chiang AK, Ho MH, Chan EY, Ha SY. Dural sinus thrombosis owing to polycythemia vera in a 12-year-old girl. Paediatr Int Child Health. 2012;32(3):167–170. PubMed

Park MJ, Shimada A, Asada H, Koike K, Tsuchida M, Hayashi Y. JAK2 mutation in a boy with polycythemia vera, but not in other pediatric hematologic disorders. Leukemia. 2006;20(8):1453–1454. PubMed

Osgood EE. Polycythemia vera: age relationships and survival. Blood. 1965;26:243–256. PubMed

Reid MM, Saunders PW, Kernahan J. Myeloproliferative disease in children: a demographic study. J Clin Pathol. 1988;41(8):883–885. PubMed PMC

McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol. 1997;15(4):173–189. PubMed

Hasle H. Incidence of essential thrombocythemia in children. Br J Haematol. 2000; 110(3):751. PubMed

Visser O, Trama A, Maynadié M, et al. RARECARE Working Group Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer. 2012;48(17): 3257–3266. PubMed

Horibe K, Saito AM, Takimoto T, et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol. 2013;98(1):74–88. PubMed

Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta- analysis. Am J Hematol. 2014;89(6):581–587. PubMed

Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129(6):680–692. PubMed PMC

Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861–1869. PubMed

Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1(1):21–30. PubMed PMC

Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer J. 2018;8(1):3. PubMed PMC

Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J. 2018;8(1):2. PubMed PMC

Alimam S, Bewley S, Chappell LC, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol. 2016;175(1):31–36. PubMed

Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–2390. PubMed

Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405. PubMed PMC

Lussana F, Carobbio A, Randi ML, et al. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythemia vera. Br J Haematol. 2014;167(4):541–546. PubMed

Landolfi R, Marchioli R, Kutti J, et al. European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114–124. PubMed

Alvarez-Larrán A, Pereira A, Guglielmelli P, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica. 2016;101(8):926–931. PubMed PMC

Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. Reye’s syndrome in the United States from 1981 through 1997. N Engl J Med. 1999;340(18):1377–1382. PubMed

Bennett MJ, Russell LK, Tokunaga C, et al. Reye-like syndrome resulting from novel missense mutations in mitochondrial medium- and short-chain l-3-hydroxy-acyl-CoA dehydrogenase. Mol Genet Metab. 2006;89(1-2):74–79. PubMed

McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol. 2011;18(3):158–165. PubMed PMC

Outcomes of allogeneic haematopoietic cell transplantation for myelofibrosis in children and adolescents: the retrospective study of the EBMT Paediatric Diseases WP

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs